Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants
Science Advances · 05.09.2025 · 11 (36)
DOI: 10.1126/sciadv.adv7922 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 05.09.2025. Verfasst von Brittni A Scruggs und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Dependovirus, Hydrogels, Genetic Therapy, Fibrin. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Subretinal injection of adeno-associated virus (AAV) is generally more efficacious and less inflammatory than intravitreal injection for retinal gene therapy. However, adverse events (e.g., chorioretinal atrophy) have been reported in many patients receiving subretinal injection of Luxturna (voretigene neparvovec-rzyl) and experimental gene therapies. Subretinal injection confines transduction to the treated area. To address this, we manufactured high-concentration fibrin hydrogels encapsulating AAV2–green fluorescent protein (AAV2- GFP ). Gels had homogeneous AAV distribution, desired mechanical properties, and retained infectivity. Epiretinal placement of fibrin–AAV2- GFP ( n = 11) was compared to subretinal ( n = 5) and intravitreal AAV2- GFP injection ( n = 3). The subretinal group exhibited inconsistent retinal pigment epithelium (RPE) transduction restricted to the injection region with severe atrophy in two cases. The intravitreal group had weak transduction and inflammation. In contrast, epiretinal hydrogels degraded within days and led to broad transduction of RPE without atrophy or inflammation. This technology could advance gene therapy for retinal degenerations and other ocular or systemic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.
- Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
- Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Brittni A Scruggs, Aubrey Berger, Emma Trncic, Raymond Iezzi, Alan D Marmorstein
Zitieren
APA
Scruggs, B. A., Berger, A., Knudsen, T., Kopp, F. N., Hill, M., Trncic, E., Anderson, K., Iezzi, R., & Marmorstein, A. D. (2025). Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants. Science Advances, 11(36). https://doi.org/10.1126/sciadv.adv7922
Vancouver
Scruggs BA, Berger A, Knudsen T, Kopp FN, Hill M, Trncic E, et al. Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants. Science Advances. 2025;11(36). doi:10.1126/sciadv.adv7922
BibTeX
@article{Scruggs2025,
author = {Scruggs, Brittni A and Berger, Aubrey and Knudsen, Travis and Kopp, Francesca N and Hill, Matthew and Trncic, Emma and Anderson, Kjersten and Iezzi, Raymond and Marmorstein, Alan D},
title = {Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {36},
doi = {10.1126/sciadv.adv7922}
}
EUVIMED